ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Angiotensin Receptor Blockers (ARBs) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Published Date: September 2024
|
Report Code: QYRE-Auto-4V7294
Home | Market Reports | Health| Health Conditions| Heart & Hypertension
Global Angiotensin Receptor Blockers ARBs Market Insights and Forecast to 2028
BUY CHAPTERS

Angiotensin Receptor Blockers (ARBs) - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-4V7294
Report
September 2024
Pages:117
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pfizer Inc
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol–Myers Squibb
Bayer
GSK
Teva Pharmaceutical

Angiotensin Receptor Blockers (ARBs) - Market Size

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years.

Angiotensin Receptor Blockers (ARBs) - Market

Angiotensin Receptor Blockers (ARBs) - Market

Angiotensin II receptor blockers (ARBs), also known as angiotensin II receptor antagonists, AT1 receptor antagonists or sartans, are a group of pharmaceuticals that modulate the renin–angiotensin system. Their main uses are in the treatment of hypertension (high blood pressure), diabetic nephropathy (kidney damage due to diabetes) and congestive heart failure. They block the activation of AT1receptors, preventing the binding of angiotensin II.
The global market for Angiotensin Receptor Blockers (ARBs) was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Angiotensin Receptor Blockers (ARBs), focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Angiotensin Receptor Blockers (ARBs) by region & country, by Type, and by Application.
The Angiotensin Receptor Blockers (ARBs) market size, estimations, and forecasts are provided in terms of sales volume (K MT) and sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angiotensin Receptor Blockers (ARBs).
Market Segmentation

Scope of Angiotensin Receptor Blockers (ARBs) - Market Report

Report Metric Details
Report Name Angiotensin Receptor Blockers (ARBs) - Market
Accounted market size in year US$ 603 billion
CAGR 5%
Base Year year
Segment by Type:
Segment by Application
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 2: Detailed analysis of Angiotensin Receptor Blockers (ARBs) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 5: Sales, revenue of Angiotensin Receptor Blockers (ARBs) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 6: Sales, revenue of Angiotensin Receptor Blockers (ARBs) in country level. It provides sigmate data by Type, and by Application for each country/region.
  • Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 9: Conclusion.

FAQ for this report

Who are the main players in the Angiotensin Receptor Blockers (ARBs) - Market report?

Ans: The main players in the Angiotensin Receptor Blockers (ARBs) - Market are Pfizer, Novartis, Merck, Astra Zeneca, Jhonson and Johnson, Eli Lilly, Sanofi, Bristol-Myers Squibb, Bayer, GSK, Teva Pharmaceutical

What are the Application segmentation covered in the Angiotensin Receptor Blockers (ARBs) - Market report?

Ans: The Applications covered in the Angiotensin Receptor Blockers (ARBs) - Market report are Hypertension, Cardiovascular Diseases, Kidney Diseases, Other

What are the Type segmentation covered in the Angiotensin Receptor Blockers (ARBs) - Market report?

Ans: The Types covered in the Angiotensin Receptor Blockers (ARBs) - Market report are Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan

Recommended Reports

Sartan Drugs Market

Hypertension Treatment Markets

Cardio-Renal Drug Markets

1 Market Overview
1.1 Angiotensin Receptor Blockers (ARBs) Product Introduction
1.2 Global Angiotensin Receptor Blockers (ARBs) Market Size Forecast
1.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales Value (2019-2030)
1.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales Volume (2019-2030)
1.2.3 Global Angiotensin Receptor Blockers (ARBs) Sales Price (2019-2030)
1.3 Angiotensin Receptor Blockers (ARBs) Market Trends & Drivers
1.3.1 Angiotensin Receptor Blockers (ARBs) Industry Trends
1.3.2 Angiotensin Receptor Blockers (ARBs) Market Drivers & Opportunity
1.3.3 Angiotensin Receptor Blockers (ARBs) Market Challenges
1.3.4 Angiotensin Receptor Blockers (ARBs) Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Angiotensin Receptor Blockers (ARBs) Players Revenue Ranking (2023)
2.2 Global Angiotensin Receptor Blockers (ARBs) Revenue by Company (2019-2024)
2.3 Global Angiotensin Receptor Blockers (ARBs) Players Sales Volume Ranking (2023)
2.4 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Company Players (2019-2024)
2.5 Global Angiotensin Receptor Blockers (ARBs) Average Price by Company (2019-2024)
2.6 Key Manufacturers Angiotensin Receptor Blockers (ARBs) Manufacturing Base Distribution and Headquarters
2.7 Key Manufacturers Angiotensin Receptor Blockers (ARBs) Product Offered
2.8 Key Manufacturers Time to Begin Mass Production of Angiotensin Receptor Blockers (ARBs)
2.9 Angiotensin Receptor Blockers (ARBs) Market Competitive Analysis
2.9.1 Angiotensin Receptor Blockers (ARBs) Market Concentration Rate (2019-2024)
2.9.2 Global 5 and 10 Largest Manufacturers by Angiotensin Receptor Blockers (ARBs) Revenue in 2023
2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angiotensin Receptor Blockers (ARBs) as of 2023)
2.10 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Valsartan
3.1.2 Telmisartan
3.1.3 Losartan
3.1.4 Irbesartan
3.1.5 Azilsartan
3.1.6 Olmesartan
3.2 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type
3.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales Value, by Type (2019-2030)
3.2.3 Global Angiotensin Receptor Blockers (ARBs) Sales Value, by Type (%) (2019-2030)
3.3 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type
3.3.1 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type (2019 VS 2023 VS 2030)
3.3.2 Global Angiotensin Receptor Blockers (ARBs) Sales Volume, by Type (2019-2030)
3.3.3 Global Angiotensin Receptor Blockers (ARBs) Sales Volume, by Type (%) (2019-2030)
3.4 Global Angiotensin Receptor Blockers (ARBs) Average Price by Type (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hypertension
4.1.2 Cardiovascular Diseases
4.1.3 Kidney Diseases
4.1.4 Other
4.2 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application
4.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales Value, by Application (2019-2030)
4.2.3 Global Angiotensin Receptor Blockers (ARBs) Sales Value, by Application (%) (2019-2030)
4.3 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application
4.3.1 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application (2019 VS 2023 VS 2030)
4.3.2 Global Angiotensin Receptor Blockers (ARBs) Sales Volume, by Application (2019-2030)
4.3.3 Global Angiotensin Receptor Blockers (ARBs) Sales Volume, by Application (%) (2019-2030)
4.4 Global Angiotensin Receptor Blockers (ARBs) Average Price by Application (2019-2030)
5 Segmentation by Region
5.1 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region
5.1.1 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region (2019-2024)
5.1.3 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region (2025-2030)
5.1.4 Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region (%), (2019-2030)
5.2 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Region
5.2.1 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Region: 2019 VS 2023 VS 2030
5.2.2 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Region (2019-2024)
5.2.3 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Region (2025-2030)
5.2.4 Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Region (%), (2019-2030)
5.3 Global Angiotensin Receptor Blockers (ARBs) Average Price by Region (2019-2030)
5.4 North America
5.4.1 North America Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
5.4.2 North America Angiotensin Receptor Blockers (ARBs) Sales Value by Country (%), 2023 VS 2030
5.5 Europe
5.5.1 Europe Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
5.5.2 Europe Angiotensin Receptor Blockers (ARBs) Sales Value by Country (%), 2023 VS 2030
5.6 Asia Pacific
5.6.1 Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
5.6.2 Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales Value by Country (%), 2023 VS 2030
5.7 South America
5.7.1 South America Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
5.7.2 South America Angiotensin Receptor Blockers (ARBs) Sales Value by Country (%), 2023 VS 2030
5.8 Middle East & Africa
5.8.1 Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
5.8.2 Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Angiotensin Receptor Blockers (ARBs) Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Angiotensin Receptor Blockers (ARBs) Sales Value
6.2.1 Key Countries/Regions Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
6.2.2 Key Countries/Regions Angiotensin Receptor Blockers (ARBs) Sales Volume, 2019-2030
6.3 United States
6.3.1 United States Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
6.3.2 United States Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Angiotensin Receptor Blockers (ARBs) Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
6.4.2 Europe Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Angiotensin Receptor Blockers (ARBs) Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
6.5.2 China Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
6.5.3 China Angiotensin Receptor Blockers (ARBs) Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
6.6.2 Japan Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Angiotensin Receptor Blockers (ARBs) Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
6.7.2 South Korea Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Angiotensin Receptor Blockers (ARBs) Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
6.8.2 Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Angiotensin Receptor Blockers (ARBs) Sales Value, 2019-2030
6.9.2 India Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
6.9.3 India Angiotensin Receptor Blockers (ARBs) Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Pfizer
7.1.1 Pfizer Company Information
7.1.2 Pfizer Introduction and Business Overview
7.1.3 Pfizer Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2019-2024)
7.1.4 Pfizer Angiotensin Receptor Blockers (ARBs) Product Offerings
7.1.5 Pfizer Recent Development
7.2 Novartis
7.2.1 Novartis Company Information
7.2.2 Novartis Introduction and Business Overview
7.2.3 Novartis Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2019-2024)
7.2.4 Novartis Angiotensin Receptor Blockers (ARBs) Product Offerings
7.2.5 Novartis Recent Development
7.3 Merck
7.3.1 Merck Company Information
7.3.2 Merck Introduction and Business Overview
7.3.3 Merck Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2019-2024)
7.3.4 Merck Angiotensin Receptor Blockers (ARBs) Product Offerings
7.3.5 Merck Recent Development
7.4 Astra Zeneca
7.4.1 Astra Zeneca Company Information
7.4.2 Astra Zeneca Introduction and Business Overview
7.4.3 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2019-2024)
7.4.4 Astra Zeneca Angiotensin Receptor Blockers (ARBs) Product Offerings
7.4.5 Astra Zeneca Recent Development
7.5 Jhonson and Johnson
7.5.1 Jhonson and Johnson Company Information
7.5.2 Jhonson and Johnson Introduction and Business Overview
7.5.3 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2019-2024)
7.5.4 Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Product Offerings
7.5.5 Jhonson and Johnson Recent Development
7.6 Eli Lilly
7.6.1 Eli Lilly Company Information
7.6.2 Eli Lilly Introduction and Business Overview
7.6.3 Eli Lilly Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2019-2024)
7.6.4 Eli Lilly Angiotensin Receptor Blockers (ARBs) Product Offerings
7.6.5 Eli Lilly Recent Development
7.7 Sanofi
7.7.1 Sanofi Company Information
7.7.2 Sanofi Introduction and Business Overview
7.7.3 Sanofi Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2019-2024)
7.7.4 Sanofi Angiotensin Receptor Blockers (ARBs) Product Offerings
7.7.5 Sanofi Recent Development
7.8 Bristol-Myers Squibb
7.8.1 Bristol-Myers Squibb Company Information
7.8.2 Bristol-Myers Squibb Introduction and Business Overview
7.8.3 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2019-2024)
7.8.4 Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Product Offerings
7.8.5 Bristol-Myers Squibb Recent Development
7.9 Bayer
7.9.1 Bayer Company Information
7.9.2 Bayer Introduction and Business Overview
7.9.3 Bayer Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2019-2024)
7.9.4 Bayer Angiotensin Receptor Blockers (ARBs) Product Offerings
7.9.5 Bayer Recent Development
7.10 GSK
7.10.1 GSK Company Information
7.10.2 GSK Introduction and Business Overview
7.10.3 GSK Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2019-2024)
7.10.4 GSK Angiotensin Receptor Blockers (ARBs) Product Offerings
7.10.5 GSK Recent Development
7.11 Teva Pharmaceutical
7.11.1 Teva Pharmaceutical Company Information
7.11.2 Teva Pharmaceutical Introduction and Business Overview
7.11.3 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Sales, Revenue and Gross Margin (2019-2024)
7.11.4 Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Product Offerings
7.11.5 Teva Pharmaceutical Recent Development
8 Industry Chain Analysis
8.1 Angiotensin Receptor Blockers (ARBs) Industrial Chain
8.2 Angiotensin Receptor Blockers (ARBs) Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Angiotensin Receptor Blockers (ARBs) Sales Model
8.5.2 Sales Channel
8.5.3 Angiotensin Receptor Blockers (ARBs) Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer
FEATURED COMPANIES
Pfizer Inc
Novartis
Merck
Astra Zeneca
Jhonson and Johnson
Eli Lilly
Sanofi
Bristol–Myers Squibb
Bayer
GSK
Teva Pharmaceutical
List of Tables
    Table 1. Angiotensin Receptor Blockers (ARBs) Market Trends
    Table 2. Angiotensin Receptor Blockers (ARBs) Market Drivers & Opportunity
    Table 3. Angiotensin Receptor Blockers (ARBs) Market Challenges
    Table 4. Angiotensin Receptor Blockers (ARBs) Market Restraints
    Table 5. Global Angiotensin Receptor Blockers (ARBs) Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Angiotensin Receptor Blockers (ARBs) Revenue Market Share by Company (2019-2024)
    Table 7. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Company (2019-2024) & (K MT)
    Table 8. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Market Share by Company (2019-2024)
    Table 9. Global Market Angiotensin Receptor Blockers (ARBs) Price by Company (2019-2024) & (USD/MT)
    Table 10. Key Manufacturers Angiotensin Receptor Blockers (ARBs) Manufacturing Base Distribution and Headquarters
    Table 11. Key Manufacturers Angiotensin Receptor Blockers (ARBs) Product Type
    Table 12. Key Manufacturers Time to Begin Mass Production of Angiotensin Receptor Blockers (ARBs)
    Table 13. Global Angiotensin Receptor Blockers (ARBs) Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Top Manufacturers Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angiotensin Receptor Blockers (ARBs) as of 2023)
    Table 15. Mergers & Acquisitions, Expansion Plans
    Table 16. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 17. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type (2019-2024) & (US$ Million)
    Table 18. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type (2025-2030) & (US$ Million)
    Table 19. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share in Value by Type (2019-2024) & (%)
    Table 20. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share in Value by Type (2025-2030) & (%)
    Table 21. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type: 2019 VS 2023 VS 2030 (K MT)
    Table 22. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type (2019-2024) & (K MT)
    Table 23. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type (2025-2030) & (K MT)
    Table 24. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share in Volume by Type (2019-2024) & (%)
    Table 25. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share in Volume by Type (2025-2030) & (%)
    Table 26. Global Angiotensin Receptor Blockers (ARBs) Price by Type (2019-2024) & (USD/MT)
    Table 27. Global Angiotensin Receptor Blockers (ARBs) Price by Type (2025-2030) & (USD/MT)
    Table 28. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 29. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application (2019-2024) & (US$ Million)
    Table 30. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application (2025-2030) & (US$ Million)
    Table 31. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share in Value by Application (2019-2024) & (%)
    Table 32. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share in Value by Application (2025-2030) & (%)
    Table 33. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application: 2019 VS 2023 VS 2030 (K MT)
    Table 34. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application (2019-2024) & (K MT)
    Table 35. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application (2025-2030) & (K MT)
    Table 36. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share in Volume by Application (2019-2024) & (%)
    Table 37. Global Angiotensin Receptor Blockers (ARBs) Sales Market Share in Volume by Application (2025-2030) & (%)
    Table 38. Global Angiotensin Receptor Blockers (ARBs) Price by Application (2019-2024) & (USD/MT)
    Table 39. Global Angiotensin Receptor Blockers (ARBs) Price by Application (2025-2030) & (USD/MT)
    Table 40. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region (2019-2024) & (US$ Million)
    Table 42. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region (2025-2030) & (US$ Million)
    Table 43. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region (2019-2024) & (%)
    Table 44. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Region (2025-2030) & (%)
    Table 45. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Region (K MT): 2019 VS 2023 VS 2030
    Table 46. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Region (2019-2024) & (K MT)
    Table 47. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Region (2025-2030) & (K MT)
    Table 48. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Region (2019-2024) & (%)
    Table 49. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Region (2025-2030) & (%)
    Table 50. Global Angiotensin Receptor Blockers (ARBs) Average Price by Region (2019-2024) & (USD/MT)
    Table 51. Global Angiotensin Receptor Blockers (ARBs) Average Price by Region (2025-2030) & (USD/MT)
    Table 52. Key Countries/Regions Angiotensin Receptor Blockers (ARBs) Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 53. Key Countries/Regions Angiotensin Receptor Blockers (ARBs) Sales Value, (2019-2024) & (US$ Million)
    Table 54. Key Countries/Regions Angiotensin Receptor Blockers (ARBs) Sales Value, (2025-2030) & (US$ Million)
    Table 55. Key Countries/Regions Angiotensin Receptor Blockers (ARBs) Sales Volume, (2019-2024) & (K MT)
    Table 56. Key Countries/Regions Angiotensin Receptor Blockers (ARBs) Sales Volume, (2025-2030) & (K MT)
    Table 57. Pfizer Company Information
    Table 58. Pfizer Introduction and Business Overview
    Table 59. Pfizer Angiotensin Receptor Blockers (ARBs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 60. Pfizer Angiotensin Receptor Blockers (ARBs) Product Offerings
    Table 61. Pfizer Recent Development
    Table 62. Novartis Company Information
    Table 63. Novartis Introduction and Business Overview
    Table 64. Novartis Angiotensin Receptor Blockers (ARBs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 65. Novartis Angiotensin Receptor Blockers (ARBs) Product Offerings
    Table 66. Novartis Recent Development
    Table 67. Merck Company Information
    Table 68. Merck Introduction and Business Overview
    Table 69. Merck Angiotensin Receptor Blockers (ARBs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 70. Merck Angiotensin Receptor Blockers (ARBs) Product Offerings
    Table 71. Merck Recent Development
    Table 72. Astra Zeneca Company Information
    Table 73. Astra Zeneca Introduction and Business Overview
    Table 74. Astra Zeneca Angiotensin Receptor Blockers (ARBs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 75. Astra Zeneca Angiotensin Receptor Blockers (ARBs) Product Offerings
    Table 76. Astra Zeneca Recent Development
    Table 77. Jhonson and Johnson Company Information
    Table 78. Jhonson and Johnson Introduction and Business Overview
    Table 79. Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 80. Jhonson and Johnson Angiotensin Receptor Blockers (ARBs) Product Offerings
    Table 81. Jhonson and Johnson Recent Development
    Table 82. Eli Lilly Company Information
    Table 83. Eli Lilly Introduction and Business Overview
    Table 84. Eli Lilly Angiotensin Receptor Blockers (ARBs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 85. Eli Lilly Angiotensin Receptor Blockers (ARBs) Product Offerings
    Table 86. Eli Lilly Recent Development
    Table 87. Sanofi Company Information
    Table 88. Sanofi Introduction and Business Overview
    Table 89. Sanofi Angiotensin Receptor Blockers (ARBs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 90. Sanofi Angiotensin Receptor Blockers (ARBs) Product Offerings
    Table 91. Sanofi Recent Development
    Table 92. Bristol-Myers Squibb Company Information
    Table 93. Bristol-Myers Squibb Introduction and Business Overview
    Table 94. Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 95. Bristol-Myers Squibb Angiotensin Receptor Blockers (ARBs) Product Offerings
    Table 96. Bristol-Myers Squibb Recent Development
    Table 97. Bayer Company Information
    Table 98. Bayer Introduction and Business Overview
    Table 99. Bayer Angiotensin Receptor Blockers (ARBs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 100. Bayer Angiotensin Receptor Blockers (ARBs) Product Offerings
    Table 101. Bayer Recent Development
    Table 102. GSK Company Information
    Table 103. GSK Introduction and Business Overview
    Table 104. GSK Angiotensin Receptor Blockers (ARBs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 105. GSK Angiotensin Receptor Blockers (ARBs) Product Offerings
    Table 106. GSK Recent Development
    Table 107. Teva Pharmaceutical Company Information
    Table 108. Teva Pharmaceutical Introduction and Business Overview
    Table 109. Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Sales (K MT), Revenue (US$ Million), Price (USD/MT) and Gross Margin (2019-2024)
    Table 110. Teva Pharmaceutical Angiotensin Receptor Blockers (ARBs) Product Offerings
    Table 111. Teva Pharmaceutical Recent Development
    Table 112. Key Raw Materials Lists
    Table 113. Raw Materials Key Suppliers Lists
    Table 114. Angiotensin Receptor Blockers (ARBs) Downstream Customers
    Table 115. Angiotensin Receptor Blockers (ARBs) Distributors List
    Table 116. Research Programs/Design for This Report
    Table 117. Key Data Information from Secondary Sources
    Table 118. Key Data Information from Primary Sources
List of Figures
    Figure 1. Angiotensin Receptor Blockers (ARBs) Product Picture
    Figure 2. Global Angiotensin Receptor Blockers (ARBs) Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Angiotensin Receptor Blockers (ARBs) Sales Value (2019-2030) & (US$ Million)
    Figure 4. Global Angiotensin Receptor Blockers (ARBs) Sales Volume (2019-2030) & (K MT)
    Figure 5. Global Angiotensin Receptor Blockers (ARBs) Sales Price (2019-2030) & (USD/MT)
    Figure 6. Angiotensin Receptor Blockers (ARBs) Report Years Considered
    Figure 7. Global Angiotensin Receptor Blockers (ARBs) Players Revenue Ranking (2023) & (US$ Million)
    Figure 8. Global Angiotensin Receptor Blockers (ARBs) Players Sales Volume Ranking (2023) & (K MT)
    Figure 9. The 5 and 10 Largest Manufacturers in the World: Market Share by Angiotensin Receptor Blockers (ARBs) Revenue in 2023
    Figure 10. Angiotensin Receptor Blockers (ARBs) Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 11. Valsartan Picture
    Figure 12. Telmisartan Picture
    Figure 13. Losartan Picture
    Figure 14. Irbesartan Picture
    Figure 15. Azilsartan Picture
    Figure 16. Olmesartan Picture
    Figure 17. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 18. Global Angiotensin Receptor Blockers (ARBs) Sales Value Market Share by Type, 2023 & 2030
    Figure 19. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Type (2019 VS 2023 VS 2030) & (K MT)
    Figure 20. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Market Share by Type, 2023 & 2030
    Figure 21. Global Angiotensin Receptor Blockers (ARBs) Price by Type (2019-2030) & (USD/MT)
    Figure 22. Product Picture of Hypertension
    Figure 23. Product Picture of Cardiovascular Diseases
    Figure 24. Product Picture of Kidney Diseases
    Figure 25. Product Picture of Other
    Figure 26. Global Angiotensin Receptor Blockers (ARBs) Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 27. Global Angiotensin Receptor Blockers (ARBs) Sales Value Market Share by Application, 2023 & 2030
    Figure 28. Global Angiotensin Receptor Blockers (ARBs) Sales Volume by Application (2019 VS 2023 VS 2030) & (K MT)
    Figure 29. Global Angiotensin Receptor Blockers (ARBs) Sales Volume Market Share by Application, 2023 & 2030
    Figure 30. Global Angiotensin Receptor Blockers (ARBs) Price by Application (2019-2030) & (USD/MT)
    Figure 31. North America Angiotensin Receptor Blockers (ARBs) Sales Value (2019-2030) & (US$ Million)
    Figure 32. North America Angiotensin Receptor Blockers (ARBs) Sales Value by Country (%), 2023 VS 2030
    Figure 33. Europe Angiotensin Receptor Blockers (ARBs) Sales Value (2019-2030) & (US$ Million)
    Figure 34. Europe Angiotensin Receptor Blockers (ARBs) Sales Value by Country (%), 2023 VS 2030
    Figure 35. Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales Value (2019-2030) & (US$ Million)
    Figure 36. Asia Pacific Angiotensin Receptor Blockers (ARBs) Sales Value by Country (%), 2023 VS 2030
    Figure 37. South America Angiotensin Receptor Blockers (ARBs) Sales Value (2019-2030) & (US$ Million)
    Figure 38. South America Angiotensin Receptor Blockers (ARBs) Sales Value by Country (%), 2023 VS 2030
    Figure 39. Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales Value (2019-2030) & (US$ Million)
    Figure 40. Middle East & Africa Angiotensin Receptor Blockers (ARBs) Sales Value by Country (%), 2023 VS 2030
    Figure 41. Key Countries/Regions Angiotensin Receptor Blockers (ARBs) Sales Value (%), (2019-2030)
    Figure 42. Key Countries/Regions Angiotensin Receptor Blockers (ARBs) Sales Volume (%), (2019-2030)
    Figure 43. United States Angiotensin Receptor Blockers (ARBs) Sales Value, (2019-2030) & (US$ Million)
    Figure 44. United States Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
    Figure 45. United States Angiotensin Receptor Blockers (ARBs) Sales Value by Application (%), 2023 VS 2030
    Figure 46. Europe Angiotensin Receptor Blockers (ARBs) Sales Value, (2019-2030) & (US$ Million)
    Figure 47. Europe Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
    Figure 48. Europe Angiotensin Receptor Blockers (ARBs) Sales Value by Application (%), 2023 VS 2030
    Figure 49. China Angiotensin Receptor Blockers (ARBs) Sales Value, (2019-2030) & (US$ Million)
    Figure 50. China Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
    Figure 51. China Angiotensin Receptor Blockers (ARBs) Sales Value by Application (%), 2023 VS 2030
    Figure 52. Japan Angiotensin Receptor Blockers (ARBs) Sales Value, (2019-2030) & (US$ Million)
    Figure 53. Japan Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
    Figure 54. Japan Angiotensin Receptor Blockers (ARBs) Sales Value by Application (%), 2023 VS 2030
    Figure 55. South Korea Angiotensin Receptor Blockers (ARBs) Sales Value, (2019-2030) & (US$ Million)
    Figure 56. South Korea Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
    Figure 57. South Korea Angiotensin Receptor Blockers (ARBs) Sales Value by Application (%), 2023 VS 2030
    Figure 58. Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value, (2019-2030) & (US$ Million)
    Figure 59. Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
    Figure 60. Southeast Asia Angiotensin Receptor Blockers (ARBs) Sales Value by Application (%), 2023 VS 2030
    Figure 61. India Angiotensin Receptor Blockers (ARBs) Sales Value, (2019-2030) & (US$ Million)
    Figure 62. India Angiotensin Receptor Blockers (ARBs) Sales Value by Type (%), 2023 VS 2030
    Figure 63. India Angiotensin Receptor Blockers (ARBs) Sales Value by Application (%), 2023 VS 2030
    Figure 64. Angiotensin Receptor Blockers (ARBs) Industrial Chain
    Figure 65. Angiotensin Receptor Blockers (ARBs) Manufacturing Cost Structure
    Figure 66. Channels of Distribution (Direct Sales, and Distribution)
    Figure 67. Bottom-up and Top-down Approaches for This Report
    Figure 68. Data Triangulation
    Figure 69. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$3950

This license allows only one user to access the PDF.
Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Angiotensin II Receptor Blocker ARBs API Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Angiotensin Receptor Antagonists Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Angiotensin II Receptor Blockers Market Insights Forecast to 2030
Global Irbesartan Market Research Report 2024
Global AT1 Receptor Antagonists Market Research Report 2024
Global Angiotensin II Type 1 Receptor AT1R Antagonists Market Research Report 2024
Global Angiotensin II Receptor Market Research Report 2024
Global Renin Angiotensin System RAS Inhibitor Market Research Report 2024
Angiotensin Converting Enzyme Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Non Peptide Drugs of Angiotensin II Receptor Antagonist Market Research Report 2024
Global Sartans Market Research Report 2024
Angiotensin Converting Enzyme ACE Inhibitors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Sartan series Drugs Market Research Report 2024
Renin Angiotensin System RAS Acting Agent Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Irbesartan Tablets Market Insights Forecast to 2030
Global Aldosterone Receptor Antagonists Market Research Report 2024
Global Androgen Receptor AR Inhibitor Market Research Report 2025
Global Valsartan Capsules Market Research Report 2024
Valsartan Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Angiotensinogen Antibody Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions